IPO Year: 2021
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/19/2024 | $14.00 → $11.00 | Overweight → Equal Weight | Wells Fargo |
| 2/15/2024 | $11.00 | Outperform | Wedbush |
| 1/3/2023 | $18.00 | Equal Weight → Overweight | Wells Fargo |
| 10/13/2022 | $22.00 | Buy | UBS |
| 8/15/2022 | $20.00 | Buy | Jefferies |
| 4/28/2022 | $19.00 | Neutral | Credit Suisse |
| 2/10/2022 | $19.00 | Equal-Weight | Wells Fargo |
| 10/14/2021 | $20.00 | Mkt Perform | SVB Leerink |
| 7/19/2021 | $30.00 | Buy | Guggenheim |
| 7/19/2021 | $40.00 | Overweight | Piper Sandler |
10-Q - Monte Rosa Therapeutics, Inc. (0001826457) (Filer)
8-K - Monte Rosa Therapeutics, Inc. (0001826457) (Filer)
DEFA14A - Monte Rosa Therapeutics, Inc. (0001826457) (Filer)
DEF 14A - Monte Rosa Therapeutics, Inc. (0001826457) (Filer)
SCHEDULE 13G - Monte Rosa Therapeutics, Inc. (0001826457) (Subject)
EFFECT - Monte Rosa Therapeutics, Inc. (0001826457) (Filer)
S-3 - Monte Rosa Therapeutics, Inc. (0001826457) (Filer)
S-8 - Monte Rosa Therapeutics, Inc. (0001826457) (Filer)
10-K - Monte Rosa Therapeutics, Inc. (0001826457) (Filer)
8-K - Monte Rosa Therapeutics, Inc. (0001826457) (Filer)
Wells Fargo downgraded Monte Rosa Therapeutics from Overweight to Equal Weight and set a new price target of $11.00 from $14.00 previously
Wedbush initiated coverage of Monte Rosa Therapeutics with a rating of Outperform and set a new price target of $11.00
Wells Fargo upgraded Monte Rosa Therapeutics from Equal Weight to Overweight and set a new price target of $18.00
UBS initiated coverage of Monte Rosa Therapeutics with a rating of Buy and set a new price target of $22.00
Jefferies initiated coverage of Monte Rosa Therapeutics with a rating of Buy and set a new price target of $20.00
Credit Suisse initiated coverage of Monte Rosa Therapeutics with a rating of Neutral and set a new price target of $19.00
Wells Fargo initiated coverage of Monte Rosa Therapeutics with a rating of Equal-Weight and set a new price target of $19.00
SVB Leerink initiated coverage of Monte Rosa Therapeutics with a rating of Mkt Perform and set a new price target of $20.00
Guggenheim initiated coverage of Monte Rosa Therapeutics with a rating of Buy and set a new price target of $30.00
Piper Sandler initiated coverage of Monte Rosa Therapeutics with a rating of Overweight and set a new price target of $40.00
4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
3 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
SC 13G/A - Monte Rosa Therapeutics, Inc. (0001826457) (Subject)
SC 13G/A - Monte Rosa Therapeutics, Inc. (0001826457) (Subject)
SC 13D/A - Monte Rosa Therapeutics, Inc. (0001826457) (Subject)
SC 13D/A - Monte Rosa Therapeutics, Inc. (0001826457) (Subject)
SC 13D/A - Monte Rosa Therapeutics, Inc. (0001826457) (Subject)
SC 13D/A - Monte Rosa Therapeutics, Inc. (0001826457) (Subject)
SC 13D/A - Monte Rosa Therapeutics, Inc. (0001826457) (Subject)
SC 13G/A - Monte Rosa Therapeutics, Inc. (0001826457) (Subject)
SC 13G - Monte Rosa Therapeutics, Inc. (0001826457) (Subject)
SC 13G/A - Monte Rosa Therapeutics, Inc. (0001826457) (Subject)
VAV1-directed MRT-6160 program advancing toward multiple Phase 2 studies, enabled by Phase 1 SAD/MAD study data supporting broad potential application in immune-mediated diseases MRT-2359 Phase 1/2 study data demonstrate encouraging signals of clinical response in heavily pretreated castration-resistant prostate cancer patients resistant to AR therapy; additional results expected in H2 2025 MRT-8102, a NEK7-directed molecular glue degrader targeting diseases driven by IL-1β and the NLRP3 inflammasome, on track for IND filing in H1 2025 Cyclin E1 (CCNE1) and CDK2-directed MGD programs for the treatment of CCNE1-driven solid tumors and ER+ breast cancer advancing toward the clin
CDK2 molecular glue degrader (MGD) in combination with CDK4/6 inhibition and anti-estrogen therapy achieved superior tumor regression in vivo compared to standard of care CDK4/6 inhibition and anti-estrogen therapy CDK2 MGD delayed resistance to CDK4/6 inhibition in vitro and displayed superior selectivity versus clinical-stage CDK2 inhibitors BOSTON, April 28, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company will present preclinical data on the potential of its highly selective cyclin-dependent kinase 2 (CDK2)-directed molecular glue
Results of the MRT-6160 Phase 1 SAD/MAD study demonstrate deep VAV1 degradation of greater than 90%, significant T and B cell functional inhibition as well as significant inhibition of cytokine release from T and B cells following ex-vivo stimulation, and favorable safety/tolerability profile; data support clear path to Phase 2 studies and broad potential applications in immune-mediated diseases Phase 1/2 study of MRT-2359 demonstrates encouraging signals of clinical response in castration-resistant prostate cancer (CRPC) patients resistant to AR therapy, including confirmed RECIST response; CRPC cohort will be focus moving forward with additional Phase 1/2 results expected in H2 2025; depr
Company to present clinical results from Phase 1 SAD/MAD study of VAV1-directed molecular glue degrader MRT-6160 and Phase 1/2 study of MRT-2359 in MYC-driven solid tumors Conference call and webcast planned for 8 a.m. ET on March 20, 2025 BOSTON, March 11, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will present a pipeline update including clinical results from its Phase 1 SAD/MAD study of the VAV1-directed MGD MRT-6160 and its Phase 1/2 study of MRT-2359 in MYC-driven solid tumors. A conference call and webcast are planned for
BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 2:30 p.m. EST. A webcast of the presentation will be accessible via the "Events & Presentations" section of Monte Rosa's website at ir.monterosatx.com, and an archived version will be made available for 30 days following the presentation. About Monte RosaMonte Rosa Therapeutics is a clinical-stage biotechnology company developing highly select
Initial clinical data from Phase 1 SAD/MAD study of VAV1-directed molecular glue degrader (MGD) MRT-6160 expected in Q1 2025 Additional clinical results from Phase 1/2 study of MRT-2359 in MYC-driven solid tumors, including biomarker and activity data, anticipated in Q1 2025 MRT-8102, a NEK7-directed MGD targeting diseases driven by IL-1β and the NLRP3 inflammasome, on track for IND filing in H1 2025 Year-end cash and equivalents expected to be $377 million as of December 31, 2024 (unaudited) and anticipated to fund operations into 2028 through multiple anticipated proof-of-concept clinical readouts Company to present at J.P. Morgan Healthcare Conference on Tuesday, January 14, at 5:15 p
BOSTON, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 5:15 p.m. PST. A webcast of the presentation will be accessible via the "Events & Presentations" section of Monte Rosa's website at ir.monterosatx.com, and an archived version will be made available for 30 days following the presentation. About Monte RosaMonte Rosa Therapeutics is a clinical-stage biotechnology company developing highly
BOSTON, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the appointment of Eric A. Hughes, M.D, Ph.D., to its Board of Directors. Dr. Hughes is currently Executive Vice President, Global R&D and Chief Medical Officer of Teva Pharmaceuticals and brings decades of biopharmaceutical industry leadership experience to Monte Rosa. "I am very excited to welcome Dr. Eric Hughes to the Monte Rosa Board of Directors," said Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics. "Eric brings extensive experience building and lea
CDK2-directed MGD drove deep tumor regression in preclinical models of HR-positive/HER2-negative breast cancer when combined with either a CDK4/6 inhibitor or a CDK4/6 inhibitor and endocrine therapy Potential to provide more sustained responses in a difficult-to-treat patient population, while avoiding toxicities typically associated with limited selectivity of CDK2 inhibitors BOSTON, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company will present preclinical data on the potential of its highly selective cyclin-dependent kinase
BOSTON, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the closing of the Company's previously announced global exclusive development and commercialization license agreement with Novartis to advance VAV1-directed MGDs, including MRT-6160. Under the terms of the agreement, Novartis will obtain exclusive worldwide rights to develop, manufacture, and commercialize MRT-6160 and other VAV1 MGDs and will be responsible for all clinical development and commercialization, starting with Phase 2 clinical studies. Monte Rosa remains responsible for co
4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
Results of the MRT-6160 Phase 1 SAD/MAD study demonstrate deep VAV1 degradation of greater than 90%, significant T and B cell functional inhibition as well as significant inhibition of cytokine release from T and B cells following ex-vivo stimulation, and favorable safety/tolerability profile; data support clear path to Phase 2 studies and broad potential applications in immune-mediated diseases Phase 1/2 study of MRT-2359 demonstrates encouraging signals of clinical response in castration-resistant prostate cancer (CRPC) patients resistant to AR therapy, including confirmed RECIST response; CRPC cohort will be focus moving forward with additional Phase 1/2 results expected in H2 2025; depr
Company to present clinical results from Phase 1 SAD/MAD study of VAV1-directed molecular glue degrader MRT-6160 and Phase 1/2 study of MRT-2359 in MYC-driven solid tumors Conference call and webcast planned for 8 a.m. ET on March 20, 2025 BOSTON, March 11, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will present a pipeline update including clinical results from its Phase 1 SAD/MAD study of the VAV1-directed MGD MRT-6160 and its Phase 1/2 study of MRT-2359 in MYC-driven solid tumors. A conference call and webcast are planned for
Optimal levels of degradation of GSPT1 in peripheral blood mononuclear cells and tumors observed at all doses, consistent with preclinical studies Tumor size reductions observed in patients with biomarker-positive tumors Safety profile supports further clinical development of MRT-2359 Conference call and webcast at 8:00 a.m. ET today BOSTON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced interim data from the Phase 1 dose escalation part of its ongoing Phase 1/2 open-label, multicenter study of MRT-2359 in patients with MYC-driven solid tumors, including l
BOSTON, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the appointment of Eric A. Hughes, M.D, Ph.D., to its Board of Directors. Dr. Hughes is currently Executive Vice President, Global R&D and Chief Medical Officer of Teva Pharmaceuticals and brings decades of biopharmaceutical industry leadership experience to Monte Rosa. "I am very excited to welcome Dr. Eric Hughes to the Monte Rosa Board of Directors," said Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics. "Eric brings extensive experience building and lea
BOSTON, July 26, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the appointment of Anthony M. Manning, Ph.D., to its Board of Directors. Dr. Manning is a highly accomplished drug discovery leader in the field of autoimmune and inflammatory diseases. "Dr. Manning brings extensive knowledge and experience in the field of immunology and inflammation to our Board of Directors, and we're delighted to have him on our team," said Markus Warmuth, M.D., CEO of Monte Rosa. "Tony's experience developing multiple first-in-class therapeutics for the treatment of
BOSTON, March 23, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the appointment of Jan Skvarka, Ph.D., MBA to its Board of Directors. Dr. Skvarka is an accomplished biopharmaceutical executive bringing over three decades of extensive operational, strategic and financial expertise to the Board. "We are delighted to have Dr. Skvarka join our Board of Directors, bringing his extensive experience as a life sciences leader to the team," said Markus Warmuth, M.D., CEO of Monte Rosa. "Having served as the CEO of two clinical-stage companies, Jan has demon
Phase 1/2 clinical trial evaluating MRT-2359 for treatment of MYC-driven solid tumors ongoingDisclosure of initial data from Phase 1 arm of study expected in second half of 2023MRT-2359 received Fast Track designation from FDA for treatment of patients with previously treated, metastatic non-small cell lung cancer (NSCLC) with L-MYC or N-MYC expressionNomination of multiple development candidates anticipated in 2023Year-end 2022 cash balance of approximately $268 million, with cash runway into 2025 BOSTON, March 16, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, to
BOSTON, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a biotechnology company developing novel molecular glue degrader medicines, today announced the promotion of Jullian Jones, Ph.D., J.D., MBA, to Chief Business Officer. Dr. Jones, who previously served as Senior Vice President, Head of Business Development, has over a decade of experience directing development and partnership transactions within the life sciences industry. "We are delighted to appoint Jullian to the role of Chief Business Officer. In addition to playing a pivotal role in Monte Rosa's upsized $255.6 million IPO earlier this year, Jullian's fingerprints are all over some of the most subst